Saturday 17 October 2026
Export BBLG’s income statement to Excel — free account
Bone Biologics Corp.
BBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 67.7% and free cash flow fell 13.0%, each against the same quarter a year earlier.
0.40
0.01
+2.56%
Follow BBLG
Bone Biologics Corp. (BBLG) P/E ratio
Bone Biologics Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.1× (May 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.1×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| BBLG Bone Biologics Corp. | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| LYRA Lyra Therapeutics, Inc. compare | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)